Stockscreener 앱 받기
184.85
2.33%
-4.41
시간 외 거래:
185.60
0.75
+0.41%
Abbvie Inc 주식(ABBV)의 최신 뉴스
Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business
AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News
Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily
Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com
What drives AbbVie Inc. stock priceFree Technical Analysis Support - PrintWeekIndia
AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest
Is AbbVie Inc. a good long term investmentMassive stock growth - PrintWeekIndia
What analysts say about AbbVie Inc. stockConsistently superior profits - Autocar Professional
AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN
AbbVie Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia
All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year - The Motley Fool
AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN
AbbVie’s Real-World Study on Upadacitinib for Atopic Dermatitis: Key Insights for Investors - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Potential Game-Changer for B-NHL Treatment - TipRanks
AbbVie’s Observational Study on Upadacitinib: A Boost for Adolescent Atopic Dermatitis Treatment - TipRanks
AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer? - TipRanks
AbbVie’s Upadacitinib Study: A New Hope for Hidradenitis Suppurativa? - TipRanks
AbbVie’s Venetoclax Study Update: Long-Term Safety in Focus - TipRanks
AbbVie’s Long-term Study on Bimatoprost SR: A Potential Game-Changer in Glaucoma Treatment - TipRanks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Why AbbVie Is a Strong Buy for Long-Term Investors in 2025 - FXEmpire
AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment - TipRanks
Glenmark Pharma, a BSE 500 stock, has rallied 34% in 1 month! AbbVie's licensing deal a big positive - Upstox
Here's How to Play AbbVie Stock as it Reaches Golden Cross - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Glenmark Pharma Will Turn Cash Positive With AbbVies Licensing Deal: S&P - NDTV Profit
AbbVie’s New Study on Crohn’s Disease Therapies: A Potential Game Changer? - TipRanks
AbbVie’s New Study on CLL Treatments: Market Implications and Investor Insights - TipRanks
AbbVie’s Oriahnn Study: Evaluating Hair Loss in Women with Uterine Fibroids - TipRanks
AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks
AbbVie’s Venetoclax Study in Greece: A Closer Look at CLL Treatment Outcomes - TipRanks
AbbVie’s Real-World Study on Upadacitinib for Crohn’s Disease: Key Insights for Investors - TipRanks
AbbVie’s Real-World Study on OZURDEX: A Closer Look at Market Implications - TipRanks
AbbVie’s Pediatric IBS-D Study: A Potential Game-Changer for Eluxadoline - TipRanks
AbbVie Completes Phase 1 Trial of ALIA-1758: Key Insights for Investors - TipRanks
AbbVie: Why I Set A $175 Buy Order (NYSE:ABBV) - Seeking Alpha
Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times
Glenmark Pharma will turn cash positive with AbbVie's licensing deal S P - theweek.in
Immunology Market Growth in Future Scope 2025-2032 | AbbVie - openPR.com
AbbVie's (NYSE:ABBV) Investors Will Be Pleased With Their Strong 138% Return Over the Last Five Years - 富途牛牛
AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company - Yahoo Finance
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
0.40%
0.10%
자본화:
|
볼륨(24시간):